Table 4. Plasma main group results for total and percent cystatin C.
Total Cystatin C | Perecent Cystatin C | |
Mean (ug/ml) ± S.E.M. | Mean (%)± S.E.M. | |
ALS (n = 43) | 0.818±0.024 | 1.06×10−3±3.36×10−5 |
DC (n = 11) | 0.861±0.048 | 1.12×10−3±6.78×10−5 |
HC (n = 31) | 0.705±0.023 | 0.89×10−3±3.17×10−5 |
Significance of Model Main Effects (p-values) | ||
Diagnosis | 0.001* | <0.001* |
Gender | 0.457 | 0.293 |
Age at Draw | 0.004* | 0.003* |
Pairwise Comparisons by Diagnosis (p-values) | ||
ALS vs. DC | 0.442 | 0.419 |
ALS vs. HC | 0.001* | <0.001* |
DC vs. HC | 0.004* | 0.002* |
Both measures of cystatin C differed significantly by age at draw and by diagnostic category. Cystatin C levels were significantly elevated in ALS patients and disease controls relative to healthy controls but there were no differences in cystatin C levels between ALS patients and disease controls. Asterisks indicate statistical significance at p<0.05.